Sarcoid-like reaction related to ALK-ROS inhibitors in lung cancer patients

被引：0
|
作者：
Morin, Clara [1 ,2 ]
Villeneuve, Thomas [1 ]
Norkowski, Emma [3 ]
Rosencher, Lise [4 ,5 ]
Cadranel, Jacques [4 ,5 ]
Mazieres, Julien [1 ,2 ]
机构：
[1] Univ Hosp Toulouse, Pulmonol Dept, 24 Chemin Pouvourville, F-31059 Toulouse, France
[2] Univ Toulouse III Paul Sabatier, Ctr Rech Cancerol Toulouse CRCT, Inserm, CNRS, 2 Ave Hubert Curien, F-31100 Toulouse, France
[3] Medipath, Pathol, 116 Route Espagne, F-31100 Toulouse, France
[4] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, 4 Rue Chine, F-75020 Paris, France
[5] Sorbonne Univ, 4 Rue Chine, F-75020 Paris, France
来源：
RESPIRATORY MEDICINE AND RESEARCH | 2024年 / 86卷
关键词：
Non-small cell lung cancer; ALK; ROS1; Targeted therapy; Drug-induced sarcoidosis-like reaction; Safety;
D O I：
10.1016/j.resmer.2024.101138
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] ALK and ROS1 as a joint target for the treatment of lung cancer: a review
    Puig de la Bellacasa, Raimon
    Karachaliou, Niki
    Estrada-Tejedor, Roger
    Teixido, Jordi
    Costa, Carlota
    Borrell, Jose I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (02) : 72 - 86
  • [22] ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non-Small-Cell Lung Cancer?
    Toyokawa, Gouji
    Seto, Takashi
    CLINICAL LUNG CANCER, 2014, 15 (05) : 313 - 319
  • [23] ALK and ROS1 Testing on Lung Cancer Cytologic Samples: Perspectives
    Pisapia, Pasquale
    Lozano, Maria D.
    Vigliar, Elena
    Bellevicine, Claudio
    Pepe, Francesco
    Malapelle, Umberto
    Troncone, Giancarlo
    CANCER CYTOPATHOLOGY, 2017, 125 (11) : 817 - 830
  • [24] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [25] Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer
    Ge, Liangqing
    Shi, Ruizheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (07): : 10330 - 10339
  • [26] Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy
    Li, Yingxue
    Lv, Yanna
    Zhang, Cheng
    Fu, Binyu
    Liu, Yue
    Hu, Jinxing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 257
  • [27] Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 71 - 80
  • [28] Molecular & Clinical Status of Current Biomarkers: EGFR, ALK, ROS, MET of Lung Cancer in North Indian Patients
    Suryavanshi, Moushumi
    Kumar, Dushyant
    Panigrahi, Manoj
    Choudhary, Meenakshi
    Mehta, Anurag
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S965 - S965
  • [29] Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer
    Pinto, Joseph A.
    Raez, Luis E.
    Domingo, Gelenis
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (04) : 385 - 390
  • [30] Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants
    Mitiushkina, Natalia, V
    Tiurin, Vladislav, I
    Iyevleva, Aglaya G.
    Kholmatov, Maxim M.
    Filippova, Elena A.
    Moiseyenko, Fedor, V
    Levchenko, Nikita E.
    Sardaryan, Ivan S.
    Odintsova, Svetlana, V
    Lozhkina, Alexandra M.
    Volkov, Nikita M.
    Karaseva, Nina A.
    Moiseyenko, Vladimir M.
    Orlov, Sergey, V
    Imyanitov, Evgeny N.
    BIOCHIMIE, 2018, 154 : 19 - 24
12345